NCT01349088 - Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer | Biotech Hunter

Timeline

Start Date

December 31, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2018

Conditions

Breast CancerMetastatic Breast CancerStage IV Breast Cancer

Interventions

DRUG

Ixabepilone

Patients will receive ixabepilone at 40 mg/m2.

DRUG

Capecitabine

Patients will receive capecitabine at 2000 mg/m2.

DRUG

Motesanib

Patient will receive motesanib at 100mg or 125mg once daily dependent on outcome of Phase I, which will involve the first 3-6 patients.

Trial Locations (1)

Thomas Jefferson University, Philadelphia